The drug was not associated with an increased risk for below-knee amputations in an observational study of more than 700,000 patients with type 2 diabetes in the OBSERVE-4D study (Canagliflozin vs Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation for Patients with T2DM — A Real-World Analysis of >700,000 US Patients) presented as a late-breaking poster on June 25 here at the American Diabetes Association (ADA) 2018 Scientific Sessions by John B. Buse, MD, PhD, director of the Diabetes Center at the University of North Carolina School of Medicine in Chapel Hill.